Harvard Bioscience (NASDAQ:HBIO – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of $0.07 per share and revenue of $24.15 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Harvard Bioscience Stock Performance
HBIO stock opened at $0.78 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.91 and a current ratio of 2.06. The stock has a market capitalization of $34.20 million, a price-to-earnings ratio of -2.38 and a beta of 1.25. Harvard Bioscience has a 1 year low of $0.78 and a 1 year high of $4.70. The stock’s fifty day moving average is $1.64 and its two-hundred day moving average is $2.19.
Institutional Investors Weigh In On Harvard Bioscience
A hedge fund recently raised its stake in Harvard Bioscience stock. Bank of America Corp DE raised its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO – Free Report) by 44.4% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 38,883 shares of the medical instruments supplier’s stock after buying an additional 11,948 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Harvard Bioscience worth $82,000 as of its most recent SEC filing. 80.87% of the stock is owned by institutional investors.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
See Also
- Five stocks we like better than Harvard Bioscience
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Best Stocks Under $5.00
- Tesla Stock: Finding a Bottom May Take Time
- 3 Healthcare Dividend Stocks to Buy
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
